期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 28, 期 31, 页码 4249-4262出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v28.i31.4249
关键词
Hepatitis B virus; Vaccine; Immune response; Antibodies; Neutralizing
The safety and efficacy of the hepatitis B virus (HBV) vaccine has been proven after more than four decades of implementation. However, challenges such as low coverage rate for newborns and reaching the adult population in a timely manner still exist. Recently developed novel vaccine formulations show promising performance and bring hope for achieving the goal of hepatitis control by 2030.
After more than four decades of hepatitis B virus (HBV) vaccine implementation, its safety and efficacy in preventing HBV infection have been proven and several milestones have been achieved. Most countries have included HBV immunization schedules in their health policies and progress has been made regarding universalization of the first HBV vaccine dose at birth. All of these actions have significantly contributed to reducing both the incidence of HBV infection and its related complications. However, there are still many drawbacks to overcome. The main concerns are the deficient coverage rate of the dose at birth and the large adult population that has not been reached timely by universal immunization. Additionally, the current most widely used second-generation vaccines do not induce protective immunity in 5% to 10% of the population, particularly in people over 40-years-old, obese (body mass index > 25 kg/m(2)), heavy smokers, and patients undergoing dialysis or infection with human immunodeficiency virus. Recently developed and approved novel vaccine formulations using more potent adjuvants or multiple antigens have shown better performance, particularly in difficult settings. These advances re-launch the expectations of achieving the World Health Organization's objective of completing hepatitis control by 2030.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据